scholarly journals Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (29) ◽  
pp. 48253-48262 ◽  
Author(s):  
Zheng Ren ◽  
Jinping Sun ◽  
Xinfang Sun ◽  
Hongtao Hou ◽  
Ke Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Targeted Agents ◽  
Efficacy And Safety ◽  
Molecular Targeted Agents ◽  
Gastric Cancer Patients

scholarly journals Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Jun-hua Zhao ◽  
Peng Gao ◽  
Yong-xi Song ◽  
Jing-xu Sun ◽  
Xiao-wan Chen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Gastric Cancer Patients

scholarly journals Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: a systematic review and meta-analysis

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Niko Kemi ◽  
Maarit Eskuri ◽  
Joonas H. Kauppila
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Gastric Adenocarcinoma ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Tumour Stroma ◽  
Potential Prognostic Factor ◽  
Gastric Cancer Patients

Abstract Tumour-stroma ratio (TSR) is a novel potential prognostic factor in cancers and based on the proportions of stroma and tumour area. The prognostic value of TSR in gastric cancer is incompletely known. The aim of this study was to estimate prognostic significance of TSR in gastric adenocarcinoma. A search of PubMed (MEDLINE), Web of Science, EMBASE, Cochrane and Scopus databases was performed. A meta-analysis was conducted on five-year survival in gastric cancer patients using inverse variance random-effects methods. The literature search yielded 5329 potential titles, of which a total of seven studies were eligible. Results of six studies including a total of 1779 patients were pooled in the meta-analysis. Only 23 (1.3%) of the patients received neoadjuvant therapy. All six studies had a cut-off of 50% for the proportion of stroma when dividing the patients into low- and high stroma groups. Low TSR (high amount of stroma) was strongly associated with increased five-year mortality (hazard ratio 2.19, 95% CI 1.69–2.85). In conclusion, TSR is a strong prognostic factor in gastric cancer. It could be used to estimate prognosis of gastric cancer patients not receiving neoadjuvant chemotherapy. Further studies including patients receiving neoadjuvant therapy are recommended.

The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis

Tumor Biology ◽  
2014 ◽  
Vol 35 (9) ◽  
pp. 8721-8731 ◽  
Author(s):  
Kong-Kong Wei ◽  
Lei Jiang ◽  
Yao-Yao Wei ◽  
Yu-Feng Wang ◽  
Xuan-Kun Qian ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Platinum Based Chemotherapy ◽  
Ercc1 Expression ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document